{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:45:56Z","timestamp":1785854756460,"version":"3.56.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1097\/01.crd.0000148845.74124.c0","type":"journal-article","created":{"date-parts":[[2005,4,15]],"date-time":"2005-04-15T04:01:12Z","timestamp":1113537672000},"page":"118-124","source":"Crossref","is-referenced-by-count":15,"title":["Interactions of High Salt Intake and the Response of the Cardiovascular System to Aldosterone"],"prefix":"10.1097","volume":"13","author":[{"given":"Paul R.","family":"Conlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199601043340103","article-title":"Blood pressure and end-stage renal disease in men.","volume":"334","author":"Klag","year":"1996","journal-title":"N Engl J Med"},{"issue":"5 suppl","key":"R2-3-20210203","first-page":"I33","article-title":"Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease.","volume":"13","author":"Stamler","year":"1989","journal-title":"Hypertension"},{"key":"R3-3-20210203","first-page":"271","article-title":"Harrison's Principles of Internal Medicine. 15th ed.","author":"Singer","year":"2001"},{"key":"R6-3-20210203","first-page":"809","article-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed.","author":"Jackson","year":"2001"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/01.CIR.0000030935.89559.04","article-title":"Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure.","volume":"106","author":"Jorde","year":"2002","journal-title":"Circulation"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study.","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"issue":"suppl N","key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","article-title":"Aldosterone escape during ACE inhibitor therapy in chronic heart failure.","volume":"16","author":"Struthers","year":"1995","journal-title":"Eur Heart J"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/014107680109400803","article-title":"Aldosterone as a determinant of cardiovascular and renal dysfunction.","volume":"94","author":"Epstein","year":"2001","journal-title":"J R Soc Med"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","article-title":"Pathophysiological effects of aldosterone in cardiovascular tissues.","volume":"12","author":"Rocha","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","article-title":"Vascular aldosterone. Biosynthesis and a link to angiotensin II\u2013induced hypertrophy of vascular smooth muscle cells.","volume":"269","author":"Hatakeyama","year":"1994","journal-title":"J Biol Chem"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1677\/jme.0.0240321","article-title":"Expression of 11\u03b2-hydroxylase and aldosterone synthase genes in the rat brain.","volume":"24","author":"MacKenzie","year":"2000","journal-title":"J Mol Endocrinol"},{"key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","article-title":"Aldosterone production is activated in failing ventricle in humans.","volume":"103","author":"Mizuno","year":"2001","journal-title":"Circulation"},{"issue":"suppl N","key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/eurheartj\/16.suppl_N.92","article-title":"Aldosterone: intracellular receptors in human heart.","volume":"16","author":"Bonvalet","year":"1995","journal-title":"Eur Heart J"},{"key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0006-8993(85)91291-0","article-title":"Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markers in vitro.","volume":"361","author":"Coirini","year":"1985","journal-title":"Brain Res"},{"key":"R17-3-20210203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ajh\/7.1.100","article-title":"Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells.","volume":"7","author":"Kornel","year":"1994","journal-title":"Am J Hypertens"},{"key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11906-000-0027-x","article-title":"Spironolactone in congestive heart failure.","volume":"2","author":"Soberman","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00045415-200203000-00008","article-title":"Aldosterone as a mediator in cardiovascular injury.","volume":"10","author":"Stier","year":"2002","journal-title":"Cardiol Rev"},{"key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s000590050024","article-title":"Aldosterone and myocardial fibrosis in heart failure.","volume":"25","author":"Brilla","year":"2000","journal-title":"Herz"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1006\/jmcc.1997.0612","article-title":"Myocardial fibrosis associated with aldosterone or angiotensin administration.","volume":"30","author":"Ramires","year":"1998","journal-title":"J Mol Cell Cardiol"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11906-000-0041-z","article-title":"The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.","volume":"2","author":"Hameedi","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.","volume":"85","author":"Ramires","year":"2000","journal-title":"Am J Cardiol"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/cs1020381","article-title":"Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.","volume":"102","author":"Satoh","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0008-6363(97)00097-7","article-title":"Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion.","volume":"35","author":"Sun","year":"1997","journal-title":"Cardiovasc Res"},{"key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","article-title":"Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients.","volume":"19","author":"Duprez","year":"1998","journal-title":"Eur Heart J"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.jhh.1000737","article-title":"Impaired baroreflex function and arterial compliance in primary aldosteronism.","volume":"13","author":"Veglio","year":"1999","journal-title":"J Hum Hypertens"},{"key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy.","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure.","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.","volume":"27","author":"Rossi","year":"1996","journal-title":"Hypertension"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0895-7061(02)03199-0","article-title":"Aldosterone-induced cardiac damage: focus on blood pressure independent effects.","volume":"16","author":"Schmidt","year":"2003","journal-title":"Am J Hypertens"},{"key":"R32-3-20210203","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"R33-3-20210203","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/cvr\/28.12.1863","article-title":"Aldosterone and cardiac fibrosis: in vitro studies.","volume":"28","author":"Fullerton","year":"1994","journal-title":"Cardiovasc Res"},{"key":"R34-3-20210203","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000159159","article-title":"Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts?","volume":"33","author":"Kohler","year":"1996","journal-title":"J Vasc Res"},{"key":"R35-3-20210203","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart.","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R36-3-20210203","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/endo.142.8.8339","article-title":"Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration.","volume":"142","author":"Fujisawa","year":"2001","journal-title":"Endocrinology"},{"key":"R37-3-20210203","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"R38-3-20210203","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.","volume":"39","author":"Martinez","year":"2002","journal-title":"Hypertension"},{"key":"R39-3-20210203","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats.","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"R40-3-20210203","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"R41-3-20210203","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1527-3466.2001.tb00064.x","article-title":"Eplerenone: a selective aldosterone receptor antagonist (SARA).","volume":"19","author":"Delyani","year":"2001","journal-title":"Cardiovasc Drug Rev"},{"key":"R42-3-20210203","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis.","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"R43-3-20210203","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","article-title":"Spironolactone improves angiotensin-induced vascular changes and oxidative stress.","volume":"40","author":"Virdis","year":"2002","journal-title":"Hypertension"},{"key":"R44-3-20210203","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/ndt\/16.11.2146","article-title":"Influence of aldosterone vs endothelin receptor antagonism on renovascular function in liquorice-induced hypertension.","volume":"16","author":"Quaschning","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R45-3-20210203","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.HYP.37.2.801","article-title":"Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension.","volume":"37","author":"Quaschning","year":"2001","journal-title":"Hypertension"},{"key":"R46-3-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1291\/hypres.24.99","article-title":"High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.","volume":"24","author":"Sato","year":"2001","journal-title":"Hypertens Res"},{"key":"R47-3-20210203","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R48-3-20210203","first-page":"1279","article-title":"Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure.","volume":"43","author":"Kasama","year":"2002","journal-title":"J Nucl Med"},{"key":"R49-3-20210203","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"For the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R50-3-20210203","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R51-3-20210203","doi-asserted-by":"crossref","first-page":"23A","DOI":"10.1016\/S0895-7061(02)02332-4","article-title":"On behalf of the Eplerenone 017 Investigators. Efficacy and safety of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in patients with left ventricular hypertrophy (017) [abstract].","volume":"15","author":"Pitt","year":"2002","journal-title":"Am J Hypertens"},{"key":"R52-3-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1291\/hypres.23.25","article-title":"Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients.","volume":"23","author":"Sato","year":"2000","journal-title":"Hypertens Res"},{"key":"R53-3-20210203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy.","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"R54-3-20210203","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1471-4892(01)00022-4","article-title":"Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.","volume":"1","author":"McMahon","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"R55-3-20210203","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1345\/aph.1C027","article-title":"Eplerenone\u2014a novel selective aldosterone blocker.","volume":"36","author":"Zillich","year":"2002","journal-title":"Ann Pharmacother"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.crd.0000148845.74124.c0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:46:37Z","timestamp":1785851197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-200505000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.crd.0000148845.74124.c0","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}